| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Mammalian Cell Banking Market Size 2023 |
USD 298.2 Million |
| Mammalian Cell Banking Market, CAGR |
13.66% |
| Mammalian Cell Banking Market Size 2032 |
USD 1,843.17 Million |
Market Overview:
The global demand for mammalian cell banking was valued at USD 298.2 Million in 2023 and is expected to reach USD 1,843.17 Million in 2032, growing at a CAGR of 13.66% between 2024 and 2032.
Several factors have contributed to this remarkable expansion. The increasing prevalence of chronic diseases and the growing global population have heightened the need for innovative therapeutics, boosting the demand for mammalian cell banking solutions. Additionally, increased investment in biopharmaceutical research and development, driven by the recognized efficacy of biologics over traditional pharmaceuticals, has significantly augmented the demand for these services.
Technological advancements have also revolutionized mammalian cell banking, enabling precise and efficient generation, storage, and retrieval of cell lines. Automated systems and robotics have streamlined the process, reducing contamination risks and human error while maximizing throughput and reproducibility. The integration of advanced analytical techniques, such as next-generation sequencing and mass spectrometry, has allowed researchers to characterize cell lines with unprecedented accuracy, enhancing the understanding of cellular behavior and therapeutic efficacy.
Adopting mammalian cell banking in cell-based therapies and regenerative medicine has emerged as a key market driver. With a growing emphasis on personalized medicine, there has been a shift towards developing cell-based therapies tailored to individual genetic profiles and disease susceptibilities. Mammalian cell banking facilitates the generation of patient-specific cell lines for therapeutic applications, including cancer immunotherapy and tissue regeneration.
Furthermore, the expanding scope of biotechnology and bio-manufacturing has increased the demand for mammalian cell banking services, particularly in producing recombinant proteins, monoclonal antibodies, and viral vectors for gene therapy. The scalability and versatility of mammalian cell lines make them indispensable for producing complex biologics, enabling cost-effective and high-yield manufacturing processes that meet stringent regulatory standards.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers:
Increasing Demand for Biopharmaceuticals:
The growing demand for biopharmaceuticals is a primary driver propelling the mammalian cell banking market. According to a government survey, the global biopharmaceutical market has seen a significant increase in investment, with a reported 15% annual growth rate in R&D expenditures. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and cell-based therapies, have gained prominence due to their effectiveness in treating various diseases such as cancer, autoimmune disorders, and genetic diseases. For instance, the National Science Foundation reported that state government R&D expenditures in health-related fields increased by 12% in 2021.
Advancements in Cell Therapy and Regenerative Medicine:
The rapid advancements in cell therapy and regenerative medicine are driving the expansion of the mammalian cell banking market. Cell-based therapies, such as stem cell therapies and CAR-T cell immunotherapy, hold immense promise for treating previously incurable diseases and injuries. The integration of advanced technologies, such as next-generation sequencing and mass spectrometry, has enhanced the precision and efficiency of cell banking processes, further supporting market expansion.
Regulatory Compliance and Quality Assurance:
Regulatory compliance and quality assurance are pivotal in shaping the mammalian cell banking landscape. Strict regulatory requirements govern mammalian cell line storage, handling, and documentation to ensure product safety, efficacy, and traceability. Pharmaceutical companies and contract manufacturing organizations (CMOs) are under increasing pressure to adhere to regulatory guidelines set forth by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Technological Advancements in Cell Banking Solutions:
Technological advancements in cell banking solutions drive innovation and efficiency in the mammalian market. Emerging technologies such as automated cell banking systems, cryopreservation techniques, and single-cell cloning methodologies are revolutionizing the way mammalian cells are stored, characterized, and distributed. These advancements enable researchers and biopharmaceutical companies to streamline their workflows, improve cell line stability, and enhance the reproducibility of experimental results.
Market Trends:
Increasing Demand for Biopharmaceuticals Drives Growth:
The mammalian cell banking market is witnessing a notable surge in demand, primarily fueled by the rising need for biopharmaceuticals. Biopharmaceutical products, including monoclonal antibodies, recombinant proteins, and vaccines, are being increasingly adopted for various therapeutic applications. For instance, the U.S. biopharmaceutical sector directly supports more than 900,000 jobs and a total of more than 4.4 million jobs across the economy.
Technological Advancements Enhance Cell Banking Processes:
Technological advancements are revolutionizing mammalian cell banking processes, improving efficiency and scalability. Innovations such as automated cell culture systems, advanced cryopreservation techniques, and high-throughput screening methods are streamlining cell line development and storage. For example, advancements in protein expression and clone screening have significantly improved the speed and efficiency of generating robust and highly productive cell lines for large-scale production of protein therapeutics.
Growing Investments in Regenerative Medicine and Cell Therapy:
The growing investments in regenerative medicine and cell therapy significantly impact the mammalian cell banking market. Stem cells and other mammalian cells play a pivotal role in these cutting-edge therapies, serving as the foundation for tissue engineering, organ transplantation, and personalized medicine. For instance, nearly $20 billion in funding flowed into biotech companies developing cell, gene, and tissue-based therapies in 2020, widely eclipsing the total invested in 2019.
Increasing Focus on Biosafety and Regulatory Compliance:
With stringent regulations governing the production and use of biopharmaceuticals, there is a heightened focus on biosafety and regulatory compliance within the mammalian cell banking market. Industry stakeholders are prioritizing implementing robust quality control measures and adherence to Good Manufacturing Practices (GMP) to ensure cell banks’ safety, purity, and integrity.
Rising Adoption of Personalized Medicine and Cell-Based Therapies:
The paradigm shift towards personalized medicine and cell-based therapies is driving the adoption of mammalian cell banking solutions. Personalized medicine, which tailor treatments to individual patients based on their genetic makeup and disease profile, relies heavily on genetically diverse cell lines.
Market Restraints and Challenges:
Regulatory Hurdles and Compliance Requirements:
Navigating through stringent regulatory frameworks poses a significant challenge for mammalian cell banking market players. Regulatory authorities impose stringent guidelines to ensure cell-based products’ safety, efficacy, and quality. Compliance with Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and other regulatory standards demands substantial investments in infrastructure, technology, and skilled personnel.
High Cost of Cell Banking Procedures:
The high cost associated with mammalian cell banking procedures acts as a major restraint in market expansion. Establishing and maintaining cell banks entail substantial expenses related to infrastructure, equipment, reagents, and skilled personnel. Additionally, stringent quality control measures and compliance requirements escalate operational costs.
Limited Availability of Skilled Workforce:
The scarcity of skilled professionals proficient in mammalian cell culture techniques presents a significant challenge for the industry. Cultivating and banking mammalian cells require specialized expertise in cell culture, aseptic techniques, cryopreservation, and quality control protocols. However, the demand for skilled cell biologists and technicians surpasses the available talent pool, leading to recruitment challenges and talent retention issues.
Risk of Contamination and Cross-Contamination:
Maintaining the purity and authenticity of cell lines is critical for the integrity and reproducibility of research outcomes and therapeutic applications. However, the risk of contamination and cross-contamination remains a persistent challenge in mammalian cell banking. Contaminants such as bacteria, fungi, mycoplasma, and adventitious agents can compromise cell lines’ viability, stability, and safety, leading to experimental failures and regulatory setbacks. Implementing robust contamination control strategies, stringent quality assurance protocols, and advanced detection techniques is imperative to mitigate these risks and uphold the credibility of cell banking processes.
Ethical and Legal Concerns in Cell Sourcing and Research:
Ethical considerations surrounding the sourcing of mammalian cells and their use in research and therapeutic applications pose ethical and legal dilemmas for stakeholders. The use of human-derived cell lines raises ethical concerns regarding patient consent, privacy, and potential exploitation. Furthermore, intellectual property rights and patent disputes often impede collaborative research efforts and hinder the commercialization of cell-based products.
Key Players:
- Thermo Fisher Scientific
- Merck KGaA
- Lonza Group
- GE Healthcare
- Sartorius AG
- WuXi AppTec
- Charles River Laboratories
- ATCC (American Type Culture Collection)
- CellBank Australia
- Cell Culture Technologies LLC
Recent Developments
- On August 8, 2019, Sartorius Stedim Biotech unveiled novel services tailored for the generation of mammalian cell banks.
- As of March 1, 2021, Eurofins DiscoverX Corporation disclosed the acquisition of Beacon Discovery, Inc. This strategic move aligns with Eurofins’ commitment to the pharmaceutical sector by providing specialized expertise and a proven track record in enhancing drug discovery and advancing novel therapeutic solutions.
- On April 5, 2022, Merck KGaA finalized the acquisition of MAST (Modular Automated Sampling Technology) from Lonza, bolstering its portfolio and capabilities in the realm of automated sampling technology.
Segmentation Analysis:
By Cell:
Firstly, segmentation by cell type elucidates the diverse range of cells utilized in banking processes, including stem cells, primary cells, and continuous cell lines. Stem cells, with their regenerative potential and ability to differentiate into various cell types, represent a significant segment within the market, catering to diverse research and therapeutic applications.
By Technology:
Technological segmentation underscores the pivotal role of advanced methodologies in cell banking. Innovations such as cryopreservation, automated cell banking systems, and novel preservation solutions enhance the efficiency and viability of stored cells. These technologies not only streamline the banking process but also ensure the preservation of cellular integrity, thereby contributing to the reliability of downstream applications.
By Application:
Application-based segmentation highlights the multifaceted utility of mammalian cell banking across research, drug development, regenerative medicine, and bioproduction. From basic scientific inquiries to developing cutting-edge therapeutics, cell banking is a foundational element underpinning diverse biomedical endeavors. Its significance extends to bioproduction facilities where consistent access to high-quality cell lines is essential for the scalable manufacture of biologics and vaccines.
By End-Use:
End-user segmentation delineates the varied stakeholders driving demand within the mammalian cell banking market. Academic and research institutions constitute a prominent segment, leveraging cell banking services to support fundamental research and translational studies. Biopharmaceutical companies, biotechnology firms, and contract research organizations (CROs) constitute another critical segment, relying on cell banking for drug discovery, preclinical testing, and therapeutic development initiatives.
By Region:
Geographically, regional segmentation reflects disparities in market dynamics, regulatory frameworks, and healthcare infrastructure. While North America and Europe remain key hubs for biomedical research and innovation, emerging economies in Asia-Pacific exhibit substantial growth potential fueled by increasing investments in healthcare infrastructure and research capabilities. Moreover, regional variations in disease prevalence and therapeutic priorities influence the demand for mammalian cell banking services across different markets.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Segments:
Cell Type:
- CHO
- BHK
- NS0
- YB2/0 & P2/0
- HEK293 & Derivatives
- HELA
Technology:
Application:
End User:
- Academic & Research Institute
- Biopharmaceutical Companies
- CROs
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East & Africa (MEA)
Regional Analysis:
North America stands as a prominent hub within this domain, commanding a substantial market share owing to robust investments in biotechnology and healthcare infrastructure. The region’s advanced research facilities and regulatory frameworks foster an environment conducive to cell banking activities. With a strong presence of key industry players and a culture of innovation, North America asserts its dominance, claiming a significant portion of the mammalian cell banking market.
The mammalian cell banking market in Europe showcases a competitive landscape marked by a rich history of scientific research and technological advancements. With their emphasis on research and development, European countries contribute significantly to the global market share. The region’s stringent regulatory standards ensure quality control and adherence to ethical guidelines, instilling stakeholder confidence. Despite facing regulatory complexities and economic fluctuations, Europe maintains a noteworthy presence in the mammalian cell banking market, bolstered by strategic collaborations and investments in cutting-edge technologies.
Asia Pacific emerges as a rapidly growing market for mammalian cell banking, propelled by increasing investments in biotechnology and pharmaceutical sectors. Countries like China, Japan, and India spearhead the region’s expansion, fueled by growing healthcare expenditure and rising demand for personalized medicine. Asia Pacific’s thriving biopharmaceutical industry, coupled with government initiatives to promote research and development, augments the market’s trajectory well. As key players recognize the region’s potential, strategic partnerships and expansions further amplify Asia Pacific’s influence in the global mammalian cell banking landscape.
Latin America and the Middle East & Africa regions exhibit nascent yet promising prospects within the mammalian cell banking market. Latin America’s evolving biotechnology sector, coupled with favorable regulatory reforms, presents opportunities for market growth. Similarly, the Middle East & Africa region, buoyed by increasing investments in healthcare infrastructure and biopharmaceutical research, emerges as a potential frontier for cell banking activities. While these regions currently account for a smaller share of the global market, concerted efforts to enhance research capabilities and infrastructure are poised to drive significant expansion in the coming years.
Future Outlook:
- The mammalian cell banking market is poised for robust expansion driven by increasing demand for biopharmaceuticals and personalized medicine.
- Technological advancements in cell culture techniques and genetic engineering will fuel innovation and efficiency within the mammalian cell banking sector.
- Rising investments in research and development initiatives worldwide will accelerate the adoption of mammalian cell banking solutions across diverse therapeutic areas.
- Regulatory reforms to streamline cell therapy and bioproduction processes will create new market growth and product development avenues.
- Strategic collaborations and partnerships between biotechnology firms, academic institutions, and pharmaceutical companies will stimulate market competitiveness and foster knowledge exchange.
- The growing emphasis on cell-based therapies and regenerative medicine approaches will elevate the significance of mammalian cell banking in the healthcare and biotechnology sectors.
- Expansion of contract manufacturing organizations (CMOs) offering mammalian cell banking services will cater to the escalating demand for scalable and customizable bioproduction solutions.
- Advancements in cryopreservation techniques and quality control protocols will enhance the viability and longevity of banked mammalian cell lines, ensuring reproducibility and reliability in downstream applications.
- Market players will increasingly focus on developing novel preservation methods and storage technologies to address the evolving needs of cell therapy developers and biopharmaceutical manufacturers.
- Emerging trends such as the integration of artificial intelligence and automation in cell banking processes will optimize workflow efficiencies, reduce operational costs, and drive market growth in the coming years.
